Hepatitis C News and Research

Latest Hepatitis C News and Research

Pfizer acquires Idun Pharmaceuticals

Pfizer today announced that it has entered into an agreement to acquire Idun Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases.

24 Feb 2005

Microsoft combs through millions of strains of human immunodeficiency virus (HIV)

Microsoft Research has pioneered promising new ways to combat one of humankind's most deadly viruses with advanced software typically used to analyze large computer databases and complex digital images, or to separate spam from legitimate e-mail.

23 Feb 2005

Association noted between certain non-lver cancers and hepatitis C

People infected with the hepatitis C virus (HCV) have a higher risk of developing non-Hodgkin's lymphoma and multiple myeloma, according to a recent study of the Swedish population.

22 Feb 2005

Antibody that neutralizes most HIV strains

A group of scientists from The Scripps Research Institute and several other institutions has solved the structure of a rare human antibody that broadly neutralizes human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS).

22 Feb 2005

Scientists have replicated hepatitis C virus (HCV) in the laboratory

For the first time, scientists have replicated hepatitis C virus (HCV) in the laboratory. The ability to replicate HCV in cell culture will allow researchers to better study the life cycle and biology of this virus and to test potential antiviral compounds, which may lead to new therapies for the liver disease that results from infection with HCV.

22 Feb 2005

Studies reveal methods viruses use to sidestep immune system

A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.

17 Feb 2005

Coffee consumption may be associated with a decreased risk of hepatocellular carcinoma

Two new studies in the February 16 issue of the Journal of the National Cancer Institute examine the effects of coffee consumption on the incidence of liver and colorectal cancers. One study found that drinking coffee daily is associated with a decreased risk of liver cancer, while the other found no association between drinking coffee or tea and the risk of colorectal cancer.

15 Feb 2005

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B Virus (HBV), an acute sometimes fatal form of viral hepatitis caused by a DNA virus that persists in the blood serum and is transmitted by sexual contact or by transfusion or by ingestion of contaminated blood or other bodily fluids.

14 Feb 2005

Eleventh Edition of the Report on Carcinogens

The Department of Health and Human Services released its Eleventh Edition of the Report on Carcinogens today, adding seventeen substances to the growing list of cancer-causing agents, bringing the total to 246.

31 Jan 2005

Needlestick injuries in healthcare workers still occurring

The latest Health Protection Agency report on the occupational exposure of healthcare workers (HCWs) to bloodborne viruses (BBVs) shows that nine healthcare workers were infected with hepatitis C through needlestick injuries over the last six years, with seven reported between July 2003 and June 2004.

27 Jan 2005

Doctors under pressure to compromise good health care for athletes

Doctors are repeatedly coming under pressure to compromise principles of good health care when treating athletes, reveals a small preliminary study in the Journal of Medical Ethics.

26 Jan 2005

Researchers attack cervical cancer

As more and more promising results of clinical trials on vaccination against human papillomaviruses are published, the more likely it becomes that an HPV vaccine will be the first licensed immunization against a sexually transmitted disease.

17 Jan 2005

Pilgrimage to Mecca comes with a few medical risks

The Hajj or Haj is the Pilgrimage to Mecca (or, "Makkah") and is the fifth of the "Five Pillars of Islam". Every able-bodied Muslim who can afford to do so is obliged to make the pilgrimage to Mecca at least once in a lifetime. Later this month about three million Muslims will gather for this major pilgrimage. But two doctors in this week's BMJ warn that the Hajj carries considerable health risks if the pilgrim is unprepared.

13 Jan 2005

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Australian drug specialist Narhex Life Sciences, has announced a partnership with one of the world’s foremost US medical research centres to evaluate its protease inhibitor Nar DG 35 Prodrug for its activity against Hepatitis C and SARS viruses.

12 Jan 2005

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Scientists in Brown Medical School, Providence, USA, have found that core promoter mutants of Hepatitis B Virus e Antigen replicate at up to 10-fold higher levels in transfected human hepatoma cells than the wild-type virus.

9 Jan 2005

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Harry Janssen (Erasmus University Medical Centre, Rotterdam, Netherlands) and colleagues assessed whether combination treatment with pegylated interferon alfa-2b and the antiviral agent lamivudine was more efficacious in treating chronic hepatitis B infection than pegylated interferon alfa-2b therapy alone.

7 Jan 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005

Hepatitis C News and Research

Latest Hepatitis C News and Research

Pfizer acquires Idun Pharmaceuticals

Microsoft combs through millions of strains of human immunodeficiency virus (HIV)

Association noted between certain non-lver cancers and hepatitis C

Antibody that neutralizes most HIV strains

Scientists have replicated hepatitis C virus (HCV) in the laboratory

Studies reveal methods viruses use to sidestep immune system

Coffee consumption may be associated with a decreased risk of hepatocellular carcinoma

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B

Eleventh Edition of the Report on Carcinogens

Needlestick injuries in healthcare workers still occurring

Doctors under pressure to compromise good health care for athletes

Researchers attack cervical cancer

Pilgrimage to Mecca comes with a few medical risks

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

PAHO dispels myths about the handling and the effects of mass casualties

Researchers discover clues to cirrhosis

Instead of chemotherapy, drugs that influence the X protein's behavior might become an alternative cancer therapy

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Hepatitis C News and Research

Latest Hepatitis C News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in